Skin gel trial offers hope for easing fragile x symptoms
NCT ID NCT04977986
Summary
This study tested whether a cannabidiol (CBD) gel applied to the skin could help reduce behavioral challenges in children and young adults with Fragile X Syndrome. Over 200 participants, aged 3 to under 30, were randomly assigned to receive either the active gel or a placebo gel for 18 weeks. The main goal was to see if the treatment was safe and if it improved symptoms like social avoidance and irritability, as reported by caregivers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amnova Clinical Research, LLC
Irvine, California, 92604, United States
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Central States Research
Tulsa, Oklahoma, 74136, United States
-
Children's National Medical center
Washington D.C., District of Columbia, 20010, United States
-
Genetics Clinics Australia
Melbourne, Victoria, 3161, Australia
-
Greenwood Genetic Center
Greenville, South Carolina, 29605, United States
-
Health New Zealand - Te Whatu Ora - Wellington Hospital
Newtown, Wellington Region, 6021, New Zealand
-
Kennedy Krieger Institute
Baltimore, Maryland, 21205, United States
-
King's College
London, United Kingdom
-
Lady Cilento Children's Hospital - South Brisbane
Brisbane, Queensland, 4101, Australia
-
Leicester Clinical Research
Leicester, United Kingdom
-
Manchester University NHS Foundation Trust
Manchester, United Kingdom
-
Penn State Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
-
Phoenix Children's Hospital
Phoenix, Arizona, 85016, United States
-
Primary Children's Hospital
Salt Lake City, Utah, 84113, United States
-
Rare Disease Research
Atlanta, Georgia, 30318, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Science 37
Culver City, California, 90230, United States
-
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics
New York, New York, 10029, United States
-
Thompson Autism Center CHOC
Orange, California, 92868, United States
-
UC Davis Health System, MIND Institute
Sacramento, California, 95817, United States
-
University of Edinburgh
Edinburgh, United Kingdom
-
University of Miami
Miami, Florida, 33136, United States
-
University of Minnesota Fragile X Clinic (Voyager Clinic)
Minneapolis, Minnesota, 55454, United States
-
University of Mississippi
Jackson, Mississippi, 39216, United States
-
Wellcome HRB Clinical Research Facility
Dublin, Ireland
-
Westmead Children's Hospital
Sydney, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.